Prometheus Biosciences Inc Net Income per Employee (RXDX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Prometheus Biosciences Inc   (NASDAQ: RXDX)
 

Prometheus Biosciences Inc Net Income per Employee

RXDX's Quarterly Results, Trends, Rankings, Statistics
Prometheus Biosciences Inc recorded a cumulative net loss of $-151 million during 12 month ending in the third quarter 2023.
The Healthcare sector has seen employees of 301 other companies achieving higher income per employee. While Prometheus Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 4284.


What is Income per Employee Ratio?






RXDX Net Income per Employee (Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,052,881 -991,273 -929,413 -859,888 -757,455
RXDX's Total Ranking # 4284 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


RXDX Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 302
Healthcare Sector # 741
Overall Market # 4284

Net Income per Employee Statistics
High Average Low
$ -165,735 $ -666,413 $ -1,052,881
(Jun 30 2014)   (Mar 31 2023)







Companies with similar Income per Employee for 12 month ending Mar 31 2023, within Healthcare Sector Income per Employee Income 12 month ending Mar 31 2023Number of Employees Mar 31 2023


Date modified: 2026-08-29T17:43:06+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.